Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Real-world orkambi study tracks 852 cystic fibrosis patients

NCT ID NCT03475381

First seen Jan 11, 2026 · Last updated Jun 22, 2026 · Updated 31 times

Summary

This study followed 852 cystic fibrosis patients aged 12 and older who started taking Orkambi outside of a clinical trial. Researchers tracked how many stopped treatment, why, and measured lung function and nutrition over one year. The goal was to see how the drug performs in real-life settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Adult CF center, Service de Pneumologie, Cochin Hospital

    Paris, Paris, 75006, France

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Ivacaftor+lumacaftor (Orkambi)

What this could lead to

If successful, this could confirm that Orkambi helps control cystic fibrosis symptoms and improve lung function in daily use.

What could go wrong

This is an observational study, not a controlled trial, so results may be less reliable. It only follows patients for one year, so long-term effects are unknown.

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.